EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Thrombopoietin-Receptor Agonism in Chemotherapy-Induced Thrombocytopenia

Birupaksha Biswas

International Journal of Contemporary Pathology · 08.06.2026 · 12 (1) · 29-30

DOI: 10.37506/8q4fbz55 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Contemporary Pathology, online erschienen am 08.06.2026. Verfasst von Birupaksha Biswas. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy-induced thrombocytopenia (CIT) is a common, dose-limiting toxicity of cytotoxic cancer therapy that frequently necessitates dose reduction, delay, or discontinuation, thereby compromising relative dose intensity and potentially diminishing therapeutic efficacy. Existing management strategies are largely supportive and do not address the underlying defect in thrombopoiesis. Romiplostim, a thrombopoietin-receptor agonist, directly stimulates megakaryocyte proliferation and platelet production. In prospective phase II studies and multicenter real-world cohorts, romiplostim has consistently demonstrated rapid and sustained platelet recovery in the majority of patients with CIT, enabling timely continuation of chemotherapy without recurrent thrombocytopenia and substantially reducing the need for platelet transfusions. Available evidence indicates an acceptable safety profile, with no clear excess in thrombotic events or cumulative marrow toxicity beyond that expected in patients with active malignancy. However, these findings are derived predominantly from phase II and observational data, and important uncertainties remain regarding predictors of response and optimal dosing strategies. Romiplostim represents a rational, mechanism-based approach to CIT with the potential to preserve chemotherapy delivery and treatment intensity; adequately powered randomized trials are required to define its role in routine oncologic practice.

Zitieren

APA

Biswas, B. (2026). Thrombopoietin-Receptor Agonism in Chemotherapy-Induced Thrombocytopenia. International Journal of Contemporary Pathology, 12(1), 29-30. https://doi.org/10.37506/8q4fbz55

Vancouver

Biswas B. Thrombopoietin-Receptor Agonism in Chemotherapy-Induced Thrombocytopenia. International Journal of Contemporary Pathology. 2026;12(1):29-30. doi:10.37506/8q4fbz55

BibTeX
@article{Biswas2026,
  author = {Biswas, Birupaksha},
  title = {Thrombopoietin-Receptor Agonism in Chemotherapy-Induced Thrombocytopenia},
  journal = {International Journal of Contemporary Pathology},
  year = {2026},
  volume = {12},
  number = {1},
  pages = {29--30},
  doi = {10.37506/8q4fbz55}
}
Kostenlos starten →